Matches in Wikidata for { <http://www.wikidata.org/entity/Q99583905> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- Q99583905 description "article scientifique publié en 2020" @default.
- Q99583905 description "artículu científicu espublizáu n'agostu de 2020" @default.
- Q99583905 description "scientific article published on 01 August 2020" @default.
- Q99583905 description "wetenschappelijk artikel" @default.
- Q99583905 description "наукова стаття, опублікована 1 серпня 2020" @default.
- Q99583905 name "Editorial Commentary: Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study" @default.
- Q99583905 name "Editorial Commentary: Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study" @default.
- Q99583905 type Item @default.
- Q99583905 label "Editorial Commentary: Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study" @default.
- Q99583905 label "Editorial Commentary: Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study" @default.
- Q99583905 prefLabel "Editorial Commentary: Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study" @default.
- Q99583905 prefLabel "Editorial Commentary: Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study" @default.
- Q99583905 P1433 Q99583905-B18B494E-64EF-4D79-AD91-D496B992816B @default.
- Q99583905 P1476 Q99583905-D12C31E7-2369-447B-820F-DE1EB106FDB6 @default.
- Q99583905 P2093 Q99583905-4A6E5B67-EAB6-45B1-85E2-39802BAC799D @default.
- Q99583905 P2093 Q99583905-68E752B0-16CF-4696-8631-8B1F491DC2F2 @default.
- Q99583905 P2860 Q99583905-10EC773A-BDC5-4887-8BED-D3D9CBFFD396 @default.
- Q99583905 P2860 Q99583905-3F72A6AB-98E2-4184-9950-A018D98A6BF8 @default.
- Q99583905 P2860 Q99583905-4161A72C-3792-4B29-A8A1-4DA978B54F1D @default.
- Q99583905 P2860 Q99583905-473EEF82-A957-400D-B863-E9CA4B9588FE @default.
- Q99583905 P2860 Q99583905-84BB9AE4-E578-4BB5-AFCB-59769F3DA20E @default.
- Q99583905 P2860 Q99583905-8D9CC87B-99CE-4B63-AEAB-09558BA9F4E4 @default.
- Q99583905 P2860 Q99583905-9CCA9CFE-9F0F-4D09-B11C-0B9FDF4EBD7E @default.
- Q99583905 P2860 Q99583905-B8128510-B7F7-4D8C-B851-E7FB5A992A57 @default.
- Q99583905 P2860 Q99583905-BA40B26D-60F5-4191-9A8A-3AC42505B1B2 @default.
- Q99583905 P2860 Q99583905-C692506B-CF07-43E5-AC7E-9CBF4ECA520E @default.
- Q99583905 P2860 Q99583905-EAF8C1A4-9760-434C-94AC-E2154E130D58 @default.
- Q99583905 P2860 Q99583905-F55B272C-9541-4A69-AA3E-AAD14AABDA48 @default.
- Q99583905 P2860 Q99583905-F748D0E0-542D-49F8-85B8-BACF6228FC4D @default.
- Q99583905 P2860 Q99583905-F77AB941-A756-4797-8622-7C9AAD2D328E @default.
- Q99583905 P2860 Q99583905-F79C711B-7D48-4D5C-BDCB-EDE0E62C5004 @default.
- Q99583905 P2860 Q99583905-FC48F6C7-2E20-4D9D-B8A4-B183731399E0 @default.
- Q99583905 P2860 Q99583905-FE13290E-1DDA-4B22-A858-AA1AFE3AD73A @default.
- Q99583905 P304 Q99583905-1963C918-B5AA-4BC3-953A-3FB7C1CC4B8F @default.
- Q99583905 P31 Q99583905-49A12537-FC71-434F-A9B7-3D4156C35952 @default.
- Q99583905 P356 Q99583905-834D84B4-999E-4C94-BA46-29D75277CA4A @default.
- Q99583905 P433 Q99583905-F12B55FE-575B-4D1F-86CB-2159AA083226 @default.
- Q99583905 P478 Q99583905-FDCB5A16-1FB3-4761-94C7-A10D071807E9 @default.
- Q99583905 P577 Q99583905-0F0E2E92-4C3A-4A5D-AED0-A990D433E06F @default.
- Q99583905 P698 Q99583905-E308027D-19AC-4591-9BDC-F76EF33FDDD1 @default.
- Q99583905 P921 Q99583905-87A5A2A2-6E5E-4351-836B-33D6EB73BC27 @default.
- Q99583905 P921 Q99583905-BD53297E-6574-4BFD-9FCF-F543B2306C78 @default.
- Q99583905 P932 Q99583905-A73B8CB1-4924-4CAA-95D2-1E8661DA5FF9 @default.
- Q99583905 P356 ATM.2020.03.217 @default.
- Q99583905 P698 32953837 @default.
- Q99583905 P1433 Q26842362 @default.
- Q99583905 P1476 "Editorial Commentary: Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study" @default.
- Q99583905 P2093 "Christopher G Wood" @default.
- Q99583905 P2093 "Mary E Westerman" @default.
- Q99583905 P2860 Q33927755 @default.
- Q99583905 P2860 Q34495684 @default.
- Q99583905 P2860 Q34633525 @default.
- Q99583905 P2860 Q34650664 @default.
- Q99583905 P2860 Q38135798 @default.
- Q99583905 P2860 Q38531440 @default.
- Q99583905 P2860 Q38859789 @default.
- Q99583905 P2860 Q40230481 @default.
- Q99583905 P2860 Q41316099 @default.
- Q99583905 P2860 Q46703065 @default.
- Q99583905 P2860 Q48686872 @default.
- Q99583905 P2860 Q50148659 @default.
- Q99583905 P2860 Q52652060 @default.
- Q99583905 P2860 Q57022736 @default.
- Q99583905 P2860 Q90179429 @default.
- Q99583905 P2860 Q91765160 @default.
- Q99583905 P2860 Q91765164 @default.
- Q99583905 P304 "1037" @default.
- Q99583905 P31 Q13442814 @default.
- Q99583905 P356 "10.21037/ATM.2020.03.217" @default.
- Q99583905 P433 "16" @default.
- Q99583905 P478 "8" @default.
- Q99583905 P577 "2020-08-01T00:00:00Z" @default.
- Q99583905 P698 "32953837" @default.
- Q99583905 P921 Q1164529 @default.
- Q99583905 P921 Q7810457 @default.
- Q99583905 P932 "7475466" @default.